drugset / Trial / NCT06763744
Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study is to assess the safety and efficacy of the CYP2C19 genotype-guided abbreviated dual antiplatelet therapy (DAPT) strategy versus the un-guided stepwise intensity de-escalation of DAPT strategy in patients with acute coronary syndrome (ACS) and high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI).
Timeline
- Start
- 2025-06-01
- Primary completion
- 2029-07-31
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aspirin | Small molecule | — | — |
| Comparator | Clopidogrel | Small molecule | — | — |
| Comparator | Prasugrel | Small molecule | — | — |
| Comparator | Ticagrelor | Small molecule | — | — |